| Laura Kay Sicht, APRN CNP | |
|
2505 Mission Dr, Jefferson City, MO 65109-9508 | |
| (573) 681-3000 | |
| Not Available |
| Full Name | Laura Kay Sicht |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 2505 Mission Dr, Jefferson City, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205612199 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2023032274 (Missouri) | Primary |
| Entity Name | Ssm Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336555275 PECOS PAC ID: 8921917352 Enrollment ID: O20040107000402 |
News Archive
The push and pull of physical force can cause profound changes in the behavior of a cell. Two studies from researchers working at the UNC Lineberger Comprehensive Cancer Center reveal how cells respond to mechanical manipulation
UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH).
An international research consortium led by investigators at Massachusetts General Hospital (MGH) and the University of Chicago has answered several questions about the genetic background of obsessive-compulsive disorder and Tourette syndrome, providing the first direct confirmation that both are highly heritable and also revealing major differences between the underlying genetic makeup of the disorders.
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).
› Verified 2 days ago
| Entity Name | Ssm Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649217837 PECOS PAC ID: 8921917352 Enrollment ID: O20070213000635 |
News Archive
The push and pull of physical force can cause profound changes in the behavior of a cell. Two studies from researchers working at the UNC Lineberger Comprehensive Cancer Center reveal how cells respond to mechanical manipulation
UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH).
An international research consortium led by investigators at Massachusetts General Hospital (MGH) and the University of Chicago has answered several questions about the genetic background of obsessive-compulsive disorder and Tourette syndrome, providing the first direct confirmation that both are highly heritable and also revealing major differences between the underlying genetic makeup of the disorders.
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Kay Sicht, APRN CNP 6803 Sunrise Acres Dr, Wardsville, MO 65101-8385 Ph: (157) 361-9131 | Laura Kay Sicht, APRN CNP 2505 Mission Dr, Jefferson City, MO 65109-9508 Ph: (573) 681-3000 |
News Archive
The push and pull of physical force can cause profound changes in the behavior of a cell. Two studies from researchers working at the UNC Lineberger Comprehensive Cancer Center reveal how cells respond to mechanical manipulation
UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH).
An international research consortium led by investigators at Massachusetts General Hospital (MGH) and the University of Chicago has answered several questions about the genetic background of obsessive-compulsive disorder and Tourette syndrome, providing the first direct confirmation that both are highly heritable and also revealing major differences between the underlying genetic makeup of the disorders.
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).
› Verified 2 days ago
Todd D Mccluskey, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3308 W Edgewood Dr, Suite B, Jefferson City, MO 65109 Phone: 573-893-7848 Fax: 573-893-1984 | |
Craig Alan Luetkemeyer, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1014 Madison St, Jefferson City, MO 65101 Phone: 573-644-6999 Fax: 573-644-7880 | |
Dr. Michael G. Steenbergen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-635-5264 Fax: 573-634-7423 | |
Dr. James J. Weiss, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-635-5264 Fax: 573-634-7423 | |
Lorrie L Campbell, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1014 Madison St, Jefferson City, MO 65101 Phone: 573-644-6999 Fax: 573-644-7880 | |
Dr. Douglas N. Smith, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3308 W Edgewood Dr, Suite B, Jefferson City, MO 65109 Phone: 573-893-7848 Fax: 573-893-1984 | |
Michael Peter Dudenhoeffer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 606 E High St, Jefferson City, MO 65101 Phone: 573-635-2211 Fax: 573-636-9350 |